Milton Packer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8056350/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes and Endocrinology,the, 2022, 10, 35-45.	11.4	29
2	Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. Circulation, 2022, 145, 184-193.	1.6	106
3	Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from <scp>EMPERORâ€</scp> Reduced. European Journal of Heart Failure, 2022, 24, 708-715.	7.1	32
4	Natriuretic peptideâ€based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from <scp>PARAGONâ€HF</scp> . European Journal of Heart Failure, 2022, 24, 672-677.	7.1	6
5	Effect of sacubitril/valsartan on investigatorâ€reported ventricular arrhythmias in <scp>PARADIGMâ€HF</scp> . European Journal of Heart Failure, 2022, 24, 551-561.	7.1	20
6	Diabetes and preâ€diabetes in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2022, 24, 497-509.	7.1	30
7	<scp>Angiotensin–neprilysin</scp> inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. European Journal of Heart Failure, 2022, 24, 1591-1598.	7.1	14
8	Do the Favorable Effects of Digoxin and SGLT2 Inhibitors Really Differ in Patients with Heart Failure and a Reduced Ejection Fraction? A Provocative Side-by-Side Examination of Trial Outcomes. Journal of Cardiac Failure, 2022, 28, 682-683.	1.7	5
9	Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from <scp>PARAGONâ€HF</scp> . European Journal of Heart Failure, 2022, 24, 794-803.	7.1	15
10	Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. European Heart Journal, 2022, 43, 416-424.	2.2	144
11	Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure. European Journal of Heart Failure, 2022, 24, 1148-1153.	7.1	11
12	Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With HeartÂFailure and Preserved EjectionÂFraction. Journal of the American College of Cardiology, 2022, 79, 1129-1137.	2.8	36
13	Atrial Fibrillation in HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2022, 10, 336-346.	4.1	18
14	Kidney function assessment and endpoint ascertainment in clinical trials. European Heart Journal, 2022, 43, 1379-1400.	2.2	8
15	Accelerated and personalized therapy for heart failure with reduced ejection fraction. European Heart Journal, 2022, 43, 2573-2587.	2.2	41
16	HF-567-01 THE BENEFIT OF AN IMPLANTABLE CARDIOVERTER DEFIBRILLATOR IN HEART FAILURE PATIENTS TREATED WITH EMPAGLIFLOZIN: AN ANALYSIS FROM THE EMPEROR-REDUCED TRIAL. Heart Rhythm, 2022, 19, S72-S73.	0.7	0
17	Prognostic Implications of N-Terminal Pro–B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved. JACC: Heart Failure, 2022, 10, 512-524.	4.1	20
18	Outcomes with empagliflozin in heart failure with preserved ejection fraction using <scp>DELIVER</scp> â€like endpoint definitions. European Journal of Heart Failure, 2022, 24, 1400-1405.	7.1	14

#	Article	IF	CITATIONS
19	Six lessons learned from the use of SGLT2 inhibitors in patients with heart failure. Nature Reviews Cardiology, 2022, 19, 499-500.	13.7	2
20	Early changes in estimated glomerular filtration rate postâ€initiation of empagliflozin in <scp>EMPERORâ€Reduced</scp> . European Journal of Heart Failure, 2022, 24, 1829-1839.	7.1	19
21	Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled. European Heart Journal, 2022, 43, 2984-2993.	2.2	30
22	Side effects and treatment initiation barriers of sodium–glucose cotransporter 2 inhibitors in heart failure: a systematic review and metaâ€analysis. European Journal of Heart Failure, 2022, 24, 1625-1632.	7.1	10
23	Biomarkerâ€driven prognostic models in chronic heart failure with preserved ejection fraction: the <scp>EMPEROR</scp> –Preserved trial. European Journal of Heart Failure, 2022, 24, 1869-1878.	7.1	21
24	Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. European Heart Journal, 2022, 43, 3435-3446.	2.2	39
25	Empagliflozin Improves Outcomes inÂPatients With HeartÂFailure and Preserved Ejection Fraction Irrespective of Age. Journal of the American College of Cardiology, 2022, 80, 1-18.	2.8	21
26	Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress. Cardiovascular Research, 2021, 117, 74-84.	3.8	51
27	Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics. American Journal of Kidney Diseases, 2021, 77, 280-286.	1.9	115
28	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. Circulation, 2021, 143, 326-336.	1.6	222
29	Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function. Circulation, 2021, 143, 310-321.	1.6	168
30	Disproportionate secondary mitral regurgitation: myths, misconceptions and clinical implications. Heart, 2021, 107, 528-534.	2.9	7
31	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. Circulation, 2021, 143, 337-349.	1.6	217
32	Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 671-680.	2.2	96
33	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 1203-1212.	2.2	114
34	Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient patient populations. European Heart Journal, 2021, 42, 4887-4890.	2.2	11
35	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGMâ€HF. Journal of the American Heart Association, 2021, 10, e019238.	3.7	20
36	Serum potassium and outcomes in heart failure with preserved ejection fraction: a postâ€hoc analysis of the <scp>PARAGONâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 776-784.	7.1	12

#	Article	IF	CITATIONS
37	Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in HeartÂFailure. Journal of the American College of Cardiology, 2021, 77, 1397-1407.	2.8	105
38	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan. Circulation: Heart Failure, 2021, 14, e008052.	3.9	13
39	Epicardial fat in heart failure with reduced versus preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 835-838.	7.1	30
40	Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. Circulation, 2021, 143, 949-958.	1.6	15
41	How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction?. Circulation, 2021, 143, 875-877.	1.6	149
42	Empagliflozin in Patients With HeartÂFailure, Reduced Ejection Fraction, and Volume Overload. Journal of the American College of Cardiology, 2021, 77, 1381-1392.	2.8	94
43	Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a <scp>PARADIGMâ€HF</scp> analysis. European Journal of Heart Failure, 2021, 23, 1346-1356.	7.1	11
44	Distinguishing Proportionate and Disproportionate Subtypes in FunctionalÂMitral Regurgitation and LeftÂVentricular Systolic Dysfunction. JACC: Cardiovascular Imaging, 2021, 14, 726-729.	5.3	13
45	Incidence and Outcomes of Pneumonia in Patients With HeartÂFailure. Journal of the American College of Cardiology, 2021, 77, 1961-1973.	2.8	35
46	What causes exertional dyspnoea in patients with atrial fibrillation? Implications for catheter ablation in patients with heart failure. European Journal of Heart Failure, 2021, 23, 797-799.	7.1	2
47	Global Differences in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2021, 14, e007901.	3.9	25
48	Effect of Empagliflozin on Cardiovascular and Kidney Outcomes in Patients with Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial. , 2021, 16, .		5
49	Cardiovascular and Kidney Outcomes with Empagliflozin in Heart Failure. , 2021, 16, .		1
50	Rapid evidenceâ€based sequencing of foundational drugs for heart failure and a reduced ejection fraction. European Journal of Heart Failure, 2021, 23, 882-894.	7.1	88
51	Pitfalls in Using Estimated Glomerular Filtration Rate Slope as a Surrogate for the Effect of Drugs on the Risk of Serious Adverse Renal Outcomes in Clinical Trials of Patients With Heart Failure. Circulation: Heart Failure, 2021, 14, e008537.	3.9	7
52	Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the <scp>HEAAL</scp> trial. European Journal of Heart Failure, 2021, 23, 1477-1484.	7.1	9
53	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 4442-4451.	2.2	38
54	Concentrationâ€dependent clinical and prognostic importance of highâ€sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the <scp>EMPEROR</scp> â€Reduced trial. European Journal of Heart Failure, 2021, 23, 1529-1538.	7.1	30

#	Article	IF	CITATIONS
55	Influence of Study Discontinuation during the Runâ€in Period on the Estimated Efficacy of Sacubitril/valsartan in the PARAGONâ€HF Trial. European Journal of Heart Failure, 2021, , .	7.1	5
56	Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the <scp>PARADIGMâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 1518-1524.	7.1	20
57	Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. American Heart Journal, 2021, 237, 45-53.	2.7	3
58	Differential Pathophysiological Mechanisms in HeartÂFailure With a Reduced or Preserved Ejection FractionÂin Diabetes. JACC: Heart Failure, 2021, 9, 535-549.	4.1	50
59	Heart Failure and a Preserved Ejection Fraction: A Side-by-Side Examination of the PARAGON-HF and EMPEROR-Preserved Trials. Circulation, 2021, 144, 1193-1195.	1.6	34
60	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. Circulation, 2021, 144, 1284-1294.	1.6	195
61	Empagliflozin and Major Renal Outcomes in Heart Failure. New England Journal of Medicine, 2021, 385, 1531-1533.	27.0	78
62	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 2021, 385, 1451-1461.	27.0	2,143
63	Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 4455-4464.	2.2	33
64	Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the <scp>EMPERORâ€Preserved</scp> trial. European Journal of Heart Failure, 2021, 23, 1798-1799.	7.1	21
65	Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association, 2021, 10, e022069.	3.7	15
66	Prognostic Importance of NT-proBNP andÂEffect of Empagliflozin in the EMPEROR-Reduced Trial. Journal of the American College of Cardiology, 2021, 78, 1321-1332.	2.8	55
67	Empagliflozin Improves Cardiovascular and Renal Outcomes in HeartÂFailure Irrespective of Systolic Blood Pressure. Journal of the American College of Cardiology, 2021, 78, 1337-1348.	2.8	52
68	Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization. Journal of Cardiac Failure, 2021, 27, 1027-1030.	1.7	0
69	Integrating High-Sensitivity Troponin T andÂSacubitril/Valsartan Treatment inÂHFpEF. JACC: Heart Failure, 2021, 9, 627-635.	4.1	21
70	The diverging role of epicardial adipose tissue in heart failure with reduced and preserved ejection fraction: not all fat is created equal. European Journal of Heart Failure, 2021, 23, 1872-1874.	7.1	5
71	The Complex Phenotypic Expressions of Functional Mitral Regurgitation. Journal of the American College of Cardiology, 2021, 78, 2422-2424.	2.8	5
72	ls Long-Standing Atrial Fibrillation a Biomarker of or Contributor to the Symptoms or Progression of Chronic Heart Failure?. American Journal of Medicine, 2020, 133, 17-18.	1.5	2

#	Article	IF	CITATIONS
73	Disproportionate functional mitral regurgitation: a new therapeutic target in patients with heart failure and a reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 23-25.	7.1	15
74	A Compelling Case for Less Aggressive Arrhythmia Management in Patients With Chronic Heart Failure and Long-Standing Atrial Fibrillation. Journal of Cardiac Failure, 2020, 26, 85-92.	1.7	3
75	Early Effects of Starting Doses of Enalapril in Patients with Chronic Heart Failure in the SOLVD Treatment Trial. American Journal of Medicine, 2020, 133, e25-e31.	1.5	29
76	Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction in Patients With Nonalcoholic Fatty Liver Disease. American Journal of Medicine, 2020, 133, 170-177.	1.5	35
77	What causes sudden death in patients with chronic heart failure and a reduced ejection fraction?. European Heart Journal, 2020, 41, 1757-1763.	2.2	78
78	HFpEF Is the Substrate for Stroke in Obesity and Diabetes Independent ofÂAtrial Fibrillation. JACC: Heart Failure, 2020, 8, 35-42.	4.1	19
79	Interplay of adenosine monophosphateâ€activated protein kinase/sirtuinâ€1 activation and sodium influx inhibition mediates the renal benefits of sodiumâ€glucose coâ€transporterâ€2 inhibitors in type 2 diabetes: A novel conceptual framework. Diabetes, Obesity and Metabolism, 2020, 22, 734-742.	4.4	57
80	Interdependence of Atrial Fibrillation and Heart Failure With a Preserved Ejection Fraction Reflects a Common Underlying Atrial and Ventricular Myopathy. Circulation, 2020, 141, 4-6.	1.6	81
81	Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment. European Journal of Heart Failure, 2020, 22, 214-227.	7.1	46
82	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction. Circulation, 2020, 141, 338-351.	1.6	244
83	Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation, 2020, 141, 352-361.	1.6	335
84	Prior HeartÂFailure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF. Journal of the American College of Cardiology, 2020, 75, 245-254.	2.8	88
85	Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 528-538.	7.1	28
86	Epicardial Adipose Tissue Inflammation Can Cause the Distinctive Pattern of Cardiovascular Disorders Seen in Psoriasis. American Journal of Medicine, 2020, 133, 267-272.	1.5	15
87	Do amiodarone and dronedarone prevent thrombo-embolic stroke by treating the atrial myopathy of patients with atrial fibrillation? A provocative hypothesis. Europace, 2020, 22, 681-683.	1.7	1
88	Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and HeartÂFailure Cause. JACC: Heart Failure, 2020, 8, 844-855.	4.1	56
89	Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGMâ€HF. ESC Heart Failure, 2020, 7, 3355-3364.	3.1	9
90	Mutual Antagonism of Hypoxia-Inducible Factor Isoforms in Cardiac, Vascular, and Renal Disorders. JACC Basic To Translational Science, 2020, 5, 961-968.	4.1	53

#	Article	IF	CITATIONS
91	Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. European Heart Journal, 2020, 41, 3363-3373.	2.2	103
92	Design of a prospective patientâ€level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. European Journal of Heart Failure, 2020, 22, 2393-2398.	7.1	19
93	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPERORâ€Preserved trial. European Journal of Heart Failure, 2020, 22, 2383-2392.	7.1	93
94	Prevalence and incidence of intraâ€ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGMâ€HF and ATMOSPHERE. European Journal of Heart Failure, 2020, 22, 2370-2379.	7.1	14
95	Beth Levine In Memoriam. European Heart Journal, 2020, 41, 2617-2617.	2.2	0
96	Molecular, Cellular, and Clinical Evidence That Sodiumâ€Glucose Cotransporter 2 Inhibitors Act as Neurohormonal Antagonists When Used for the Treatment of Chronic Heart Failure. Journal of the American Heart Association, 2020, 9, e016270.	3.7	30
97	Effectiveness of Medical Therapy for Functional MitralÂRegurgitation in HeartÂFailure With ReducedÂEjection Fraction. Journal of the American College of Cardiology, 2020, 76, 883-884.	2.8	11
98	Ten lessons from the <scp>EMPERORâ€Reduced</scp> trial. European Journal of Heart Failure, 2020, 22, 1991-1993.	7.1	6
99	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 2020, 383, 1413-1424.	27.0	2,821
100	SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet, The, 2020, 396, 819-829.	13.7	816
101	Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice. European Heart Journal, 2020, 41, 3398-3401.	2.2	20
102	Cardioprotective Effects of Sirtuin-1 and Its Downstream Effectors. Circulation: Heart Failure, 2020, 13, e007197.	3.9	103
103	Uric Acid Is a Biomarker of Oxidative Stress in the Failing Heart: Lessons Learned from Trials With Allopurinol and SGLT2 Inhibitors. Journal of Cardiac Failure, 2020, 26, 977-984.	1.7	53
104	Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation, 2020, 142, 1236-1245.	1.6	81
105	Serum potassium in the <scp>PARADIGMâ€HF</scp> trial. European Journal of Heart Failure, 2020, 22, 2056-2064.	7.1	34
106	Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care. European Heart Journal, 2020, 41, 2393-2396.	2.2	17
107	Guidelineâ€directed medical therapy for heart failure does not exist: a nonâ€judgmental framework for describing the level of adherence to evidenceâ€based drug treatments for patients with a reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 1759-1767.	7.1	41
108	Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs. Cardiovascular Diabetology, 2020, 19, 62.	6.8	67

#	Article	IF	CITATIONS
109	Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 1662-1671.	7.1	33
110	Longevity genes, cardiac ageing, and the pathogenesis of cardiomyopathy: implications for understanding the effects of current and future treatments for heart failure. European Heart Journal, 2020, 41, 3856-3861.	2.2	40
111	Role of ketogenic starvation sensors in mediating the renal protective effects of SGLT2 inhibitors in type 2 diabetes. Journal of Diabetes and Its Complications, 2020, 34, 107647.	2.3	28
112	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 2109-2117.	2.2	65
113	Mitigation of the Adverse Consequences of Nutrient Excess on the Kidney: A Unified Hypothesis to Explain the Renoprotective Effects of Sodium-Glucose Cotransporter 2 Inhibitors. American Journal of Nephrology, 2020, 51, 289-293.	3.1	18
114	Potential Role of Atrial Myopathy in the Pathogenesis of Stroke in Rheumatoid Arthritis and Psoriasis: A Conceptual Framework and Implications for Prophylaxis. Journal of the American Heart Association, 2020, 9, e014764.	3.7	9
115	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2020, 8, 372-381.	4.1	53
116	Role of Deranged Energy Deprivation Signaling in the Pathogenesis of Cardiac and Renal Disease in States of Perceived Nutrient Overabundance. Circulation, 2020, 141, 2095-2105.	1.6	61
117	Does Metformin Interfere With the Cardiovascular Benefits of SGLT2 Inhibitors? Questions About Its Role as the Cornerstone of Diabetes Treatment. American Journal of Medicine, 2020, 133, 781-782.	1.5	15
118	Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circulation: Heart Failure, 2020, 13, e006541.	3.9	96
119	New Evidence Supporting a Novel Conceptual Framework for Distinguishing Proportionate and Disproportionate Functional Mitral Regurgitation. JAMA Cardiology, 2020, 5, 469.	6.1	80
120	SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action. Diabetes Care, 2020, 43, 508-511.	8.6	147
121	How Should Physicians Assess Myocardial Contraction?. JACC: Cardiovascular Imaging, 2020, 13, 873-878.	5.3	30
122	Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium–glucose cotransporter 2 inhibitors. European Journal of Heart Failure, 2020, 22, 618-628.	7.1	76
123	Concerns about the use of metformin as a first-line agent to slow the progression of chronic kidney disease in diabetes. Diabetes Research and Clinical Practice, 2020, 160, 108024.	2.8	2
124	Impaired systemic venous capacitance: the neglected mechanism in patients with heart failure and a preserved ejection fraction?. European Journal of Heart Failure, 2020, 22, 173-176.	7.1	9
125	Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. JAMA Cardiology, 2020, 5, 432.	6.1	59
126	The prevalence and importance of frailty in heart failure with reduced ejection fraction–Âan analysis of <scp>PARADIGMâ€HF</scp> and <scp>ATMOSPHERE</scp> . European Journal of Heart Failure, 2020, 22, 2123-2133.	7.1	85

#	Article	IF	CITATIONS
127	Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. American Journal of Medicine, 2020, 133, 1187-1194.	1.5	9
128	A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. European Heart Journal, 2020, 41, 2356-2362.	2.2	38
129	Characterization, Pathogenesis, and Clinical Implications of Inflammationâ€Related Atrial Myopathy as an Important Cause of Atrial Fibrillation. Journal of the American Heart Association, 2020, 9, e015343.	3.7	57
130	Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors. Journal of the American Society of Nephrology: JASN, 2020, 31, 907-919.	6.1	81
131	Characterization of the <scp>inflammatoryâ€metabolic</scp> phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. European Journal of Heart Failure, 2020, 22, 1551-1567.	7.1	93
132	Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet, The, 2020, 396, 121-128.	13.7	376
133	Risks of Intensive Treatment of Long-Standing Atrial Fibrillation in Patients With Chronic Heart Failure With a Reduced or Preserved Ejection Fraction. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005747.	2.2	1
134	Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events. Circulation, 2019, 140, 443-445.	1.6	52
135	Why Are Physicians So Confused about Acute Heart Failure?. New England Journal of Medicine, 2019, 381, 776-777.	27.0	12
136	Evaluation of the effect of sodium–glucose coâ€ŧransporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPERORâ€Reduced trial. European Journal of Heart Failure, 2019, 21, 1270-1278.	7.1	155
137	Nonarrhythmic Sudden Cardiac Death in Chronic Heart Failure—A Preventable Event?. JAMA Cardiology, 2019, 4, 721.	6.1	4
138	Health-Related Quality of Life in HeartÂFailure With Preserved EjectionÂFraction. JACC: Heart Failure, 2019, 7, 862-874.	4.1	77
139	Digoxin Discontinuation and Outcomes inÂPatients With HeartÂFailure With Reduced EjectionÂFraction. Journal of the American College of Cardiology, 2019, 74, 617-627.	2.8	36
140	Methodological and Clinical Heterogeneity and Extraction Errors in Metaâ€Analyses of Catheter Ablation for Atrial Fibrillation in Heart Failure. Journal of the American Heart Association, 2019, 8, e013779.	3.7	5
141	Evaluation of the effects of sodium–glucose coâ€transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPERORâ€Preserved Trial. European Journal of Heart Failure, 2019, 21, 1279-1287.	7.1	205
142	Neurohormonal Antagonists AreÂPreferred to an Implantable Cardioverter-Defibrillator in Preventing Sudden Death in HeartÂFailure. JACC: Heart Failure, 2019, 7, 902-906.	4.1	7
143	Heightened risk of intensive rate control in patients with atrial fibrillation who are obese or have type 2 diabetes: A critical review and reâ€evaluation. Journal of Cardiovascular Electrophysiology, 2019, 30, 3020-3024.	1.7	5
144	Unraveling the Molecular Mechanism of Action of Empagliflozin in HeartÂFailure With Reduced Ejection Fraction WithÂorÂWithout Diabetes. JACC Basic To Translational Science, 2019, 4, 831-840.	4.1	65

#	Article	IF	CITATIONS
145	P2630Incidence and prognostic impact of new-onset left bundle branch block in patients with heart failure and reduced ejection fraction. European Heart Journal, 2019, 40, .	2.2	0
146	Contrasting Effects of Pharmacological, Procedural, and Surgical Interventions on Proportionate and Disproportionate Functional Mitral Regurgitation in Chronic Heart Failure. Circulation, 2019, 140, 779-789.	1.6	55
147	The Parable of Schrödinger's Cat and the Illusion of Statistical Significance in Clinical Trials. Circulation, 2019, 140, 799-800.	1.6	3
148	Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2019, 381, 1609-1620.	27.0	1,485
149	Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction. Circulation, 2019, 140, 1369-1379.	1.6	74
150	Redefining Heart Failure With a Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2019, 322, 1761.	7.4	48
151	Drugs That Ameliorate Epicardial Adipose Tissue Inflammation May Have Discordant Effects in Heart Failure With a Preserved Ejection Fraction as Compared With a Reduced Ejection Fraction. Journal of Cardiac Failure, 2019, 25, 986-1003.	1.7	37
152	Disease–treatment interactions in the management of patients with obesity and diabetes who have atrial fibrillation: the potential mediating influence of epicardial adipose tissue. Cardiovascular Diabetology, 2019, 18, 121.	6.8	38
153	Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion. Cardiovascular Diabetology, 2019, 18, 129.	6.8	45
154	Are healthcare systems now ready to adopt sacubitril/valsartan as the preferred approach to inhibiting the renin–angiotensin system in chronic heart failure? The culmination of a 20-year journey. European Heart Journal, 2019, 40, 3353-3355.	2.2	1
155	Major reduction in the risk of sudden cardiac death in patients with chronic heart failure with the use of drug and device combinations that favourably affect left ventricular structure. European Journal of Heart Failure, 2019, 21, 823-826.	7.1	12
156	Digoxin Use and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. American Journal of Medicine, 2019, 132, 1311-1319.	1.5	11
157	Critical role of the epicardium in mediating cardiac inflammation and fibrosis in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1765-1768.	4.4	6
158	Compelling First-Line Drug and Device Therapies for the Prevention of Sudden Death in Patients With Chronic Heart Failure and a Reduced Ejection Fraction Who Are Candidates for an Implantable Cardioverter-Defibrillator. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007430.	4.8	9
159	Outcomes and Effect of Treatment According to Etiology in HFrEF. JACC: Heart Failure, 2019, 7, 457-465.	4.1	94
160	Defining Secondary Mitral Regurgitation: Evidence that the 2017 Updated Guidelines Got it Right. Structural Heart, 2019, 3, 284-287.	0.6	0
161	Effect of catheter ablation on pre-existing abnormalities of left atrial systolic, diastolic, and neurohormonal functions in patients with chronic heart failure and atrial fibrillation. European Heart Journal, 2019, 40, 1873-1879.	2.2	43
162	Neurohormonal and Transcatheter Repair Strategies for Proportionate and Disproportionate Functional Mitral Regurgitation in Heart Failure. JACC: Heart Failure, 2019, 7, 518-521.	4.1	14

#	Article	IF	CITATIONS
163	Is Any Patient with Chronic Heart Failure Receiving the Right Dose of the Right Beta-Blocker in Primary Care?. American Journal of Medicine, 2019, 132, e761-e762.	1.5	2
164	What Have We Learned From Randomized Controlled Trials of Catheter Ablation for Atrial Fibrillation in Patients With Chronic Heart Failure?. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007222.	4.8	5
165	Electrophysiological interventions in the treatment of chronic heart failure: a comparison of the strength of evidence supporting cardiac resynchronization for electrical conduction delay and catheter ablation for atrial fibrillation. European Journal of Heart Failure, 2019, 21, 398-401.	7.1	0
166	B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan. Journal of the American College of Cardiology, 2019, 73, 1264-1272.	2.8	139
167	Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in PatientsÂWith HFrEF. Journal of the American College of Cardiology, 2019, 73, 795-806.	2.8	173
168	Income Inequality and Outcomes in HeartÂFailure. JACC: Heart Failure, 2019, 7, 336-346.	4.1	63
169	Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGMâ€HF trial. European Journal of Heart Failure, 2019, 21, 337-341.	7.1	129
170	When Cardiovascular Trials Collide. European Heart Journal, 2019, 40, 501-504.	2.2	4
171	Impact of Renal Impairment on Beta-Blocker Efficacy in PatientsÂWithÂHeartÂFailure. Journal of the American College of Cardiology, 2019, 74, 2893-2904.	2.8	39
172	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus. Circulation, 2019, 140, 2108-2118.	1.6	22
173	The conundrum of patients with obesity, exercise intolerance, elevated ventricular filling pressures and a measured ejection fraction in the normal range. European Journal of Heart Failure, 2019, 21, 156-162.	7.1	20
174	Differential Impact of Heart Failure WithÂReduced Ejection Fraction onÂMenÂandÂWomen. Journal of the American College of Cardiology, 2019, 73, 29-40.	2.8	168
175	Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. European Journal of Heart Failure, 2019, 21, 577-587.	7.1	38
176	The prognostic value of troponin T and Nâ€ŧerminal pro Bâ€ŧype natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. European Journal of Heart Failure, 2019, 21, 40-49.	7.1	54
177	Proportionate and Disproportionate Functional Mitral Regurgitation. JACC: Cardiovascular Imaging, 2019, 12, 353-362.	5.3	472
178	Higher mortality rate in patients with heart failure who are taking commonly prescribed antidiabetic medications and achieve recommended levels of glycaemic control. Diabetes, Obesity and Metabolism, 2018, 20, 1766-1769.	4.4	4
179	Derangements in adrenergic–adipokine signalling establish a neurohormonal basis for obesityâ€related heart failure with a preserved ejection fraction. European Journal of Heart Failure, 2018, 20, 873-878. ———————————————————————————————————	7.1	34
180	Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 547-554.	11.4	124

#	Article	IF	CITATIONS
181	Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure. JAMA Cardiology, 2018, 3, 498.	6.1	84
182	Are the effects of drugs to prevent and to treat heart failure always concordant? The statin paradox and its implications for understanding the actions of antidiabetic medications. European Journal of Heart Failure, 2018, 20, 1100-1105.	7.1	14
183	Augmentation of glucagonâ€like peptideâ€1 receptor signalling by neprilysin inhibition: potential implications for patients with heart failure. European Journal of Heart Failure, 2018, 20, 973-977.	7.1	26
184	Does a Target Dose or a Target Heart Rate Matter to Outcomes When Prescribing Î ² -Blockers to Patients With Chronic Heart Failure?. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004605.	2.2	5
185	Contrasting effects on the risk of macrovascular and microvascular events of antihyperglycemic drugs that enhance sodium excretion and lower blood pressure. Diabetic Medicine, 2018, 35, 707-713.	2.3	4
186	Leptin-Aldosterone-Neprilysin Axis. Circulation, 2018, 137, 1614-1631.	1.6	163
187	Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC: Heart Failure, 2018, 6, 489-498.	4.1	272
188	Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril. Circulation: Heart Failure, 2018, 11, e004745.	3.9	55
189	Data sharing in medical research. BMJ: British Medical Journal, 2018, 360, k510.	2.3	16
190	Are physicians neglecting the risk of heart failure in diabetic patients who are receiving sulfonylureas? Lessons from the TOSCA.IT trial. European Journal of Heart Failure, 2018, 20, 49-51.	7.1	12
191	Do DPP-4 Inhibitors Cause Heart Failure Events by Promoting Adrenergically Mediated Cardiotoxicity?. Circulation Research, 2018, 122, 928-932.	4.5	58
192	Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGMâ€HF). European Journal of Heart Failure, 2018, 20, 760-768.	7.1	62
193	Do sodiumâ€glucose coâ€transporterâ€2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis. Diabetes, Obesity and Metabolism, 2018, 20, 1361-1366.	4.4	75
194	Acute Heart Failure Is an Event RatherÂThan a Disease. JACC: Heart Failure, 2018, 6, 73-75.	4.1	14
195	Is metformin beneficial for heart failure in patients with type 2 diabetes?. Diabetes Research and Clinical Practice, 2018, 136, 168-170.	2.8	22
196	Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes. Diabetes Care, 2018, 41, 11-13.	8.6	76
197	Does Neprilysin Inhibition Potentiate or Minimize the Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Heart Failure?. Journal of Cardiac Failure, 2018, 24, 109-111.	1.7	5
198	Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?. American Journal of Medicine, 2018, 131, 461-463.	1.5	5

#	Article	IF	CITATIONS
199	Is the Popularity of Dipeptidyl-Peptidase-4 Inhibitors Justified? Insights From Mechanistic Studies and Clinical Trials. American Journal of Medicine, 2018, 131, e287-e289.	1.5	3
200	Have we really demonstrated the cardiovascular safety of antiâ€hyperglycaemic drugs? Rethinking the concepts of macrovascular and microvascular disease in type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 1089-1095.	4.4	6
201	Early Worsening of Renal Function After Treatment with Antihyperglycemic Drugs: A Consistent Finding in Large-Scale Trials. American Journal of Medicine, 2018, 131, 337-338.	1.5	3
202	The Future Treatment of Heart Failure?. European Heart Journal, 2018, 39, 5-7.	2.2	7
203	Do Most Obese People with Exercise Intolerance and a Normal Ejection Fraction Have Treatable Heart Failure?. American Journal of Medicine, 2018, 131, 863-864.	1.5	7
204	Response by Packer to Letter Regarding Article, "Activation and Inhibition of Sodium-Hydrogen Exchange Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure― Circulation, 2018, 137, 1981-1982.	1.6	0
205	Worsening Heart Failure During theÂUseÂof DPP-4 Inhibitors. JACC: Heart Failure, 2018, 6, 445-451.	4.1	63
206	Obesity-Related Heart Failure With a Preserved Ejection Fraction. JACC: Heart Failure, 2018, 6, 633-639.	4.1	108
207	Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials ofÂHeart Failure. JACC: Heart Failure, 2018, 6, 564-569.	4.1	43
208	Potential mechanisms underlying differences in the effect of incretin-based antidiabetic drugs on the risk of major atherosclerotic ischemic events. Journal of Diabetes and Its Complications, 2018, 32, 616-617.	2.3	0
209	Inferential characterization of the dose-response relationships of neurohormonal antagonists in chronic heart failure: A novel approach based on large-scale trials with active comparators. International Journal of Cardiology, 2018, 261, 130-133.	1.7	6
210	Why is the use of digitalis withering? Another reason that we need medical heart failure specialists. European Journal of Heart Failure, 2018, 20, 851-852.	7.1	7
211	Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European Heart Journal, 2018, 39, 26-35.	2.2	426
212	Will longâ€acting glucagonâ€like peptideâ€1 analogues recapitulate our agonizing experience with cyclic AMPâ€dependent positive inotropic agents in heart failure?. European Journal of Heart Failure, 2018, 20, 627-629.	7.1	14
213	Response by Dr Packer to the Letter of Dr Blankfield. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 99-100.	2.0	0
214	Role of the sodiumâ€hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 800-811.	4.4	10
215	Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGMâ€HF. European Journal of Heart Failure, 2018, 20, 514-522.	7.1	35
216	Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2018, 3, 1226.	6.1	38

#	Article	IF	CITATIONS
217	Future largeâ€scale clinical trials in cardiovascular medicine: challenges and uncertainties. European Journal of Heart Failure, 2018, 20, 1645-1648.	7.1	6
218	Post hoc analyses of SHIFT and PARADIGMâ€HF highlight the importance of chronic Chagas' cardiomyopathy <i>Comment on:</i> "Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial―by Bocchi <i>et al.</i> . ESC Heart Failure, 2018, 5, 1069-1071.	3.1	15
219	IGFBP7 (Insulin-Like Growth Factor–Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure. Circulation: Heart Failure, 2018, 11, e005133.	3.9	40
220	The Reply. American Journal of Medicine, 2018, 131, e427.	1.5	0
221	The epicardial adipose inflammatory triad: coronary atherosclerosis, atrial fibrillation, and heart failure with a preserved ejection fraction. European Journal of Heart Failure, 2018, 20, 1567-1569.	7.1	36
222	Growth differentiation factorâ€15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGMâ€HF trial. European Journal of Heart Failure, 2018, 20, 1701-1709.	7.1	56
223	Building Castles in the Sky. Circulation, 2018, 138, 751-753.	1.6	28
224	Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. Journal of the American College of Cardiology, 2018, 71, 2360-2372.	2.8	356
225	Potentiation of Insulin Signaling Contributes to Heart Failure inÂTypeÂ2ÂDiabetes. JACC Basic To Translational Science, 2018, 3, 415-419.	4.1	20
226	Questioning the obvious: does dyspnoea really matter in heart failure?. European Heart Journal, 2018, 39, 2822-2824.	2.2	6
227	Obesity-Associated Heart Failure as a Theoretical Target for Treatment With Mineralocorticoid Receptor Antagonists. JAMA Cardiology, 2018, 3, 883.	6.1	8
228	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circulation: Heart Failure, 2018, 11, e004962.	3.9	117
229	Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines. Cardiovascular Diabetology, 2018, 17, 9.	6.8	31
230	Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to) Tj ETQq 11. e004446	0 0 0 ₃ rgBT /	Overlock 10 ⁻
231	The Alchemist's Nightmare. Circulation, 2018, 137, 2068-2073.	1.6	25
232	The CABANA Trial: an honourable view. European Heart Journal, 2018, 39, 2770-2770.	2.2	4
233	Risk of heart failure in diabetic patients receiving sulfonylureas: reply. European Journal of Heart Failure, 2018, 20, 1372-1372.	7.1	0
234	Effect of betaâ€adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 549-556.	7.3	71

#	Article	IF	CITATIONS
235	Response by Packer to Letter Regarding Article, "Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure: A 20-Year Perspectiveâ€ŧ Circulation, 2017, 135, e892-e893.	1.6	0
236	Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. New England Journal of Medicine, 2017, 376, 1956-1964.	27.0	257
237	Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure. JACC: Heart Failure, 2017, 5, 317-326.	4.1	91
238	Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure. JACC: Heart Failure, 2017, 5, 399-407.	4.1	31
239	Tetralogy of Fallow. JACC: Heart Failure, 2017, 5, 408-410.	4.1	3
240	Sacubitril–Valsartan in Heart Failure. Annals of Internal Medicine, 2017, 166, 681.	3.9	0
241	Heart Rate and Rhythm and the BenefitÂofÂBeta-Blockers in PatientsÂWithÂHeart Failure. Journal of the American College of Cardiology, 2017, 69, 2885-2896.	2.8	198
242	Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. Lancet, The, 2017, 389, 1831-1840.	13.7	44
243	Should recommendations for clinical use be restricted to patients who were enrolled in a pivotal clinical trial?. European Journal of Heart Failure, 2017, 19, 779-781.	7.1	1
244	CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE: INSIGHTS FROM PARADIGM-HF. Journal of the American College of Cardiology, 2017, 69, 734.	2.8	1
245	EFFECT OF SACUBITRIL/VALSARTAN COMPARED WITH ENALAPRIL, ACCORDING TO ETIOLOGY IN PARADIGM-HF. Journal of the American College of Cardiology, 2017, 69, 919.	2.8	4
246	Double Vision. JACC: Heart Failure, 2017, 5, 232-235.	4.1	9
247	Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. European Heart Journal, 2017, 38, 1132-1143.	2.2	160
248	Let Us Not Forget the Long-term Safety Concerns of Sacubitril/Valsartan—Reply. JAMA Cardiology, 2017, 2, 819.	6.1	1
249	The effects of sacubitril/valsartan on coronary outcomes in PARADICM-HF. American Heart Journal, 2017, 188, 35-41.	2.7	32
250	Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 333-340.	11.4	258
251	Heart Failure With a Mid-Range Ejection Fraction. JACC: Heart Failure, 2017, 5, 805-807.	4.1	19
252	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circulation: Heart Failure, 2017, 10, .	3.9	53

#	Article	IF	CITATIONS
253	Is the Way to Someone's Heart Through Their Stomach?. Circulation: Heart Failure, 2017, 10, .	3.9	12
254	Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure. Circulation, 2017, 136, 1548-1559.	1.6	172
255	The Absence of an Ideal Observer. Circulation, 2017, 136, 1085-1086.	1.6	2
256	How have millions of people with heart failure benefited from our research over the last 10–15 years? The sounds of dead silence. European Journal of Heart Failure, 2017, 19, 1353-1354.	7.1	6
257	Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure. JAMA Cardiology, 2017, 2, 1025.	6.1	280
258	Who Should Deliver Medical Therapy for Patients With Chronic Heart Failure?. Circulation: Heart Failure, 2017, 10, .	3.9	5
259	Why Has a Run-In Period Been a Design Element in Most Landmark Clinical Trials? Analysis of the Critical Role of Run-In Periods in Drug Development. Journal of Cardiac Failure, 2017, 23, 697-699.	1.7	6
260	Health-Related Quality of Life Outcomes in PARADIGM-HF. Circulation: Heart Failure, 2017, 10, .	3.9	150
261	Role of Payers in the Development of Cardiovascular Therapeutics. Journal of the American College of Cardiology, 2017, 70, 2822-2830.	2.8	5
262	Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. Circulation: Heart Failure, 2017, 10, .	3.9	53
263	Type of Atrial Fibrillation and Outcomes inÂPatients With Heart Failure and ReducedÂEjectionÂFraction. Journal of the American College of Cardiology, 2017, 70, 2490-2500.	2.8	114
264	The Imminent Demise of Cardiovascular Drug Development. JAMA Cardiology, 2017, 2, 1293.	6.1	10
265	Angiotensin Receptor Neprilysin InhibitionÂin Heart Failure With PreservedÂEjection Fraction. JACC: Heart Failure, 2017, 5, 471-482.	4.1	238
266	Declining Risk of Sudden Death in Heart Failure. New England Journal of Medicine, 2017, 377, 41-51.	27.0	355
267	Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril. JAMA Cardiology, 2017, 2, 79.	6.1	143
268	Dementiaâ€related adverse events in <scp>PARADIGMâ€HF</scp> and other trials in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2017, 19, 129-137.	7.1	95
269	Rationale for and design of the <scp>TRUEâ€AHF</scp> trial: the effects of ularitide on the shortâ€ŧerm clinical course and longâ€ŧerm mortality of patients with acute heart failure. European Journal of Heart Failure, 2017, 19, 673-681.	7.1	31
270	Absence of an Ideal Observer II. Circulation, 2017, 136, 2400-2402.	1.6	3

#	Article	IF	CITATIONS
271	Are Meta-Analyses a Form of Medical Fake News?. Circulation, 2017, 136, 2097-2099.	1.6	33
272	Geographic variations in the PARADIGM-HF heart failure trial. European Heart Journal, 2016, 37, 3167-3174.	2.2	114
273	Efficacy of Sacubitril/Valsartan Relative toÂa Prior Decompensation. JACC: Heart Failure, 2016, 4, 816-822.	4.1	84
274	Unbelievable Folly of Clinical Trials in Heart Failure. Circulation: Heart Failure, 2016, 9, e002837.	3.9	21
275	Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting. Circulation, 2016, 133, 2254-2262.	1.6	142
276	Love of Angiotensin-Converting Enzyme Inhibitors in the Time of Cholera. JACC: Heart Failure, 2016, 4, 403-408.	4.1	18
277	Sacubitril/Valsartan Associated with Lower Declines in Health-Related Quality of Life Compared with Enalapril in Patients with Heart Failure Hospitalization. Journal of Cardiac Failure, 2016, 22, S24.	1.7	0
278	The Room Where It Happens: A Skeptic's Analysis of the New Heart Failure Guidelines. Journal of Cardiac Failure, 2016, 22, 726-730.	1.7	11
279	Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGMâ€HF trial. European Journal of Heart Failure, 2016, 18, 1228-1234.	7.1	173
280	Kicking the tyres of a heart failure trial: physician response to the approval of sacubitril/valsartan in the <scp>USA</scp> . European Journal of Heart Failure, 2016, 18, 1211-1219.	7.1	27
281	Traditional and new composite endpoints inÂheart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. European Journal of Heart Failure, 2016, 18, 482-489.	7.1	74
282	Heart Failure's Dark Secret. Circulation, 2016, 134, 629-631.	1.6	11
283	Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. Journal of the American College of Cardiology, 2016, 68, 2425-2436.	2.8	271
284	Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction. Circulation, 2016, 134, 1785-1787.	1.6	35
285	Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure. Circulation, 2016, 134, 1664-1678.	1.6	34
286	Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to) Tj ETQqC Therapy. Circulation: Heart Failure, 2016, 9, .) 0 0 rgBT 3.9	/Overlock 10 83
287	Data sharing: lessons from Copernicus and Kepler. BMJ, The, 2016, 354, i4911.	6.0	2
288	Association between Baseline, and Changes in, Health-Related Quality of Life and Death and HF	1.7	0

Hospitalization in PARADIGM-HF. Journal of Cardiac Failure, 2016, 22, S92. 288

#	Article	IF	CITATIONS
289	Angiotensin Neprilysin Inhibition for Patients With Heart Failure. JAMA Cardiology, 2016, 1, 971.	6.1	17
290	Influence of Sacubitril/Valsartan (LCZ696)ÂonÂ30-Day Readmission After Heart Failure Hospitalization. Journal of the American College of Cardiology, 2016, 68, 241-248.	2.8	101
291	Cobalt Cardiomyopathy. Circulation: Heart Failure, 2016, 9, .	3.9	52
292	Sacubitril–Valsartan in Heart Failure: Why Are More Physicians Not Prescribing It?. Annals of Internal Medicine, 2016, 165, 735.	3.9	19
293	Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ, The, 2016, 353, i1855.	6.0	95
294	Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. Circulation: Heart Failure, 2016, 9, .	3.9	52
295	Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	3.9	260
296	Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction. Circulation: Heart Failure, 2016, 9, e002744.	3.9	130
297	Influenza Vaccination in Patients WithÂChronic Heart Failure. JACC: Heart Failure, 2016, 4, 152-158.	4.1	112
298	Development of autophagy inducers in clinical medicine. Journal of Clinical Investigation, 2015, 125, 14-24.	8.2	274
299	Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. European Heart Journal, 2015, 36, 1990-1997.	2.2	335
300	Estimating the Long-Term Treatment Benefits of Sacubitril–Valsartan. New England Journal of Medicine, 2015, 373, 2289-2290.	27.0	92
301	Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. Circulation, 2015, 131, 54-61.	1.6	552
302	Decreased BECN1 mRNA Expression in Human Breast Cancer is Associated With Estrogen Receptor-Negative Subtypes and Poor Prognosis. EBioMedicine, 2015, 2, 255-263.	6.1	95
303	A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. European Heart Journal, 2015, 36, 434-439.	2.2	80
304	Renal effects of the angiotensin receptor neprilysin inhibitor <scp>LCZ696</scp> in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2015, 17, 510-517.	7.1	153
305	Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. European Respiratory Journal, 2015, 46, 405-413.	6.7	184
306	Cardiovascular Drug Development. Journal of the American College of Cardiology, 2015, 65, 1567-1582.	2.8	168

#	Article	IF	CITATIONS
307	Efficacy of LCZ696 Persists at Lower Than Target Doses in the PARADIGM-HF Trial. Journal of Cardiac Failure, 2015, 21, S9-S10.	1.7	6
308	Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores. Journal of the American College of Cardiology, 2015, 66, 2059-2071.	2.8	118
309	Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. European Heart Journal, 2015, 36, 2576-2584.	2.2	187
310	Abstract 17955: Reduction in 30-day Rehospitalization After Discharge From a Heart Failure Admission in Patients Receiving LCZ696 versus Enalapril: PARADIGM-HF. Circulation, 2015, 132, .	1.6	0
311	Elevation in High-Sensitivity Troponin T in Heart Failure and Preserved Ejection Fraction and Influence of Treatment With the Angiotensin Receptor Neprilysin Inhibitor LCZ696. Circulation: Heart Failure, 2014, 7, 953-959.	3.9	80
312	Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis. Journal of Clinical Oncology, 2014, 32, 2380-2385.	1.6	501
313	Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. European Heart Journal, 2014, 35, 3442-3451.	2.2	78
314	Impaired left atrial function in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2014, 16, 1096-1103.	7.1	194
315	Sexâ€specific cardiovascular structure and function in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2014, 16, 535-542.	7.1	184
316	Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2014, 63, 447-456.	2.8	591
317	Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, <scp>LCZ696</scp> , in patients with heart failure with preserved ejection fraction: an analysis of the <scp>PARAMOUNT</scp> trial. European Journal of Heart Failure, 2014, 16, 671-677	7.1	67
318	Baseline characteristics and treatment of patients in Prospective comparison of <scp>ARNI</scp> with <scp>ACEI</scp> to Determine Impact on Global Mortality and morbidity in Heart Failure trial (<scp>PARADIGMâ€HF</scp>). European Journal of Heart Failure, 2014, 16, 817-825.	7.1	148
319	Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. European Heart Journal, 2014, 35, 42-47.	2.2	61
320	Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. New England Journal of Medicine, 2014, 371, 993-1004.	27.0	5,052
321	Reply. Journal of the American College of Cardiology, 2014, 64, 1535-1536.	2.8	0
322	Effect of Bosentan and Sildenafil Combination Therapy on Morbidity and Mortality in Pulmonary Arterial Hypertension (PAH): Results From the COMPASS-2 Study. Chest, 2014, 146, 860A.	0.8	13
323	Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensinâ€converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADICMâ€HE). Furgean Journal of Heart Failure 2013, 15, 1062, 1073	7.1	358
324	Effect of Amlodipine on the Survival of Patients With Severe Chronic Heart Failure Due to a Nonischemic Cardiomyopathy. JACC: Heart Failure, 2013, 1, 308-314.	4.1	75

#	Article	IF	CITATIONS
325	Effect of Levosimendan on the Short-TermÂClinical Course of Patients With AcutelyÂDecompensated Heart Failure. JACC: Heart Failure, 2013, 1, 103-111.	4.1	337
326	The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet, The, 2012, 380, 1387-1395.	13.7	990
327	Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature, 2012, 481, 511-515.	27.8	975
328	The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase II Randomised-Controlled Trial. Journal of Cardiac Failure, 2012, 18, 883.	1.7	5
329	Utilization of Hepatocellular Carcinoma Surveillance Among American Patients: A Systematic Review. Journal of General Internal Medicine, 2012, 27, 861-867.	2.6	245
330	Can Brain Natriuretic Peptide Be Used to Guide the Management of Patients With Heart Failure and a Preserved Ejection Fraction?. Circulation: Heart Failure, 2011, 4, 538-540.	3.9	37
331	The Editor's Roundtable: Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk. American Journal of Cardiology, 2008, 102, 1046-1055.	1.6	3
332	Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure. JAMA - Journal of the American Medical Association, 2007, 297, 1883.	7.4	834
333	Lack of Bioequivalence between Different Formulations of Isosorbide??Dinitrate and Hydralazine and??the??Fixed-Dose Combination of??Isosorbide Dinitrate/Hydralazine. Clinical Pharmacokinetics, 2007, 46, 885-895.	3.5	15
334	Associations of Gender and Etiology With Outcomes in Heart Failure With Systolic Dysfunction. Journal of the American College of Cardiology, 2007, 49, 1450-1458.	2.8	121
335	Utility of Impedance Cardiography for the Identification of Short-Term Risk of Clinical Decompensation in Stable Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2006, 47, 2245-2252.	2.8	175
336	Controlled-Release Carvedilol in Heart Failure and Post-MI LVD: Pharmacokinetics, Pharmacodynamics and Safety. Journal of Cardiac Failure, 2006, 12, S71-S72.	1.7	0
337	Are β-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study. American Heart Journal, 2006, 151, 55-61.	2.7	16
338	Pharmacokinetic Profile of Controlled-Release Carvedilol in Patients with Left Ventricular Dysfunction Associated with Chronic Heart Failure or After Myocardial Infarction. American Journal of Cardiology, 2006, 98, 39-45.	1.6	153
339	Controlled-Release Carvedilol: A Concluding Perspective. American Journal of Cardiology, 2006, 98, 67-69.	1.6	3
340	The Seattle Heart Failure Model. Circulation, 2006, 113, 1424-1433.	1.6	1,744
341	Prognostic benefit of beta-blockers in patients not receiving ACE-Inhibitors. European Heart Journal, 2005, 26, 2154-2158.	2.2	22
342	Carvedilol reduces the costs of medical care in severe heart failure: An economic analysis of the COPERNICUS study applied to the United Kingdom. International Journal of Cardiology, 2005, 100, 143-149.	1.7	13

#	Article	IF	CITATIONS
343	Bcl-2 Antiapoptotic Proteins Inhibit Beclin 1-Dependent Autophagy. Cell, 2005, 122, 927-939.	28.9	3,204
344	Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. American Heart Journal, 2005, 150, 257-262.	2.7	45
345	Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. Journal of Cardiac Failure, 2005, 11, 12-20.	1.7	250
346	Left Heart Failure With a Normal Ejection Fraction: Identification of Different Pathophysiologic Mechanisms. Journal of Cardiac Failure, 2005, 11, 177-187.	1.7	184
347	Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failure. Canadian Journal of Cardiology, 2005, 21, 39-43.	1.7	24
348	Chronic Kidney Disease, Cardiovascular Risk, and Response to Angiotensin-Converting Enzyme Inhibition After Myocardial Infarction. Circulation, 2004, 110, 3667-3673.	1.6	185
349	Analytical and Clinical Evaluation of the Bayer ADVIA Centaur Automated B-Type Natriuretic Peptide Assay in Patients with Heart Failure: A Multisite Study. Clinical Chemistry, 2004, 50, 867-873.	3.2	131
350	Issues in regulatory guidelines for data monitoring committees. Clinical Trials, 2004, 1, 162-169.	1.6	21
351	Targeted Anticytokine Therapy in Patients With Chronic Heart Failure. Circulation, 2004, 109, 1594-1602.	1.6	1,062
352	NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. European Journal of Heart Failure, 2004, 6, 343-350.	7.1	85
353	Prognostic Impact of Plasma N-Terminal Pro–Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure. Circulation, 2004, 110, 1780-1786.	1.6	282
354	Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure. Journal of the American College of Cardiology, 2004, 43, 1423-1429.	2.8	132
355	The Warfarin and Antiplatelet Therapy in Heart Failure Trial (WATCH): rationale, design, and baseline patient characteristics. Journal of Cardiac Failure, 2004, 10, 101-112.	1.7	97
356	Key issues in trial design for ventricular assist devices: a position statement of the heart failure society of America. Journal of Cardiac Failure, 2004, 10, 91-100.	1.7	2
357	Physician global assessment of heart failure patients: comparison with patient global assessment and quality of life scores in the ATTACH trial. Journal of Cardiac Failure, 2004, 10, S80.	1.7	0
358	Effect of digoxin withdrawal in patients with chronic heart failure receiving carvedilol. Journal of Cardiac Failure, 2004, 10, S87.	1.7	0
359	Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. American Journal of Hypertension, 2004, 17, 103-111.	2.0	492
360	Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the assessment of treatment with lisinopril and survival (ATLAS) study. Clinical Therapeutics, 2004, 26, 694-703.	2.5	22

#	Article	IF	CITATIONS
361	Do β-blockers prolong survival in heart failure only by inhibiting the β1-receptor? A perspective on the results of the COMET trial. Journal of Cardiac Failure, 2003, 9, 429-443.	1.7	62
362	A device is not a drug. Journal of Cardiac Failure, 2003, 9, 155-157.	1.7	15
363	Prognostic importance of the oxidized product of catecholamines, adrenolutin, in patients with severe heart failure. American Heart Journal, 2003, 145, 926-932.	2.7	19
364	Vasopressor Response to Angiotensin II Infusion in Patients With Chronic Heart Failure Receiving Î ² -Blockers. Circulation, 2003, 107, 290-293.	1.6	15
365	Heart Failure With a Normal Ejection Fraction. Circulation, 2003, 107, 656-658.	1.6	226
366	Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure. Circulation, 2003, 107, 3133-3140.	1.6	1,401
367	Should B-Type Natriuretic Peptide Be Measured Routinely to Guide the Diagnosis and Management of Chronic Heart Failure?. Circulation, 2003, 108, 2950-2953.	1.6	107
368	Effects of Initiating Carvedilol in Patients With Severe Chronic Heart Failure. JAMA - Journal of the American Medical Association, 2003, 289, 712.	7.4	261
369	Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure. Circulation, 2002, 106, 2194-2199.	1.6	1,132
370	Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure. Circulation, 2002, 106, 920-926.	1.6	582
371	Selecting patients for heart transplantation: which patients are too well for transplant?. Current Opinion in Cardiology, 2002, 17, 137-144.	1.8	26
372	Cardiac Resynchronization in Chronic Heart Failure. New England Journal of Medicine, 2002, 346, 1845-1853.	27.0	4,365
373	The impossible task of developing a new treatment for heart failure. Journal of Cardiac Failure, 2002, 8, 193-196.	1.7	45
374	Diuretic resistance predicts mortality in patients with advanced heart failure. American Heart Journal, 2002, 144, 31-38.	2.7	322
375	ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. Journal of Heart and Lung Transplantation, 2002, 21, 189-203.	0.6	162
376	Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan. American Journal of Cardiology, 2002, 90, 969-973.	1.6	31
377	Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. Journal of Cardiac Failure, 2001, 7, 176-182.	1.7	366
378	Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. Journal of the American College of Cardiology, 2001, 37, 1692-1699.	2.8	61

#	Article	IF	CITATIONS
379	Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of a meta-analysis. American Heart Journal, 2001, 141, 899-907.	2.7	165
380	Effect of Carvedilol on Survival in Severe Chronic Heart Failure. New England Journal of Medicine, 2001, 344, 1651-1658.	27.0	2,909
381	Toleration of High Doses of Angiotensin-Converting Enzyme Inhibitors in Patients With Chronic Heart Failure. Archives of Internal Medicine, 2001, 161, 165.	3.8	76
382	Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. European Heart Journal, 2001, 22, 1601-1612.	2.2	46
383	ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and) Tj ETQq1 1 0.784	314 ⁶ rgBT	/Overlock 10
384	Race and the Response to Adrenergic Blockade with Carvedilol in Patients with Chronic Heart Failure. New England Journal of Medicine, 2001, 344, 1358-1365.	27.0	277
385	Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. European Heart Journal, 2000, 21, 1967-1978.	2.2	141
386	Acute Coronary Findings at Autopsy in Heart Failure Patients With Sudden Death. Circulation, 2000, 102, 611-616.	1.6	298
387	Ambulatory Ventricular Arrhythmias in Patients With Heart Failure Do Not Specifically Predict an Increased Risk of Sudden Death. Circulation, 2000, 101, 40-46.	1.6	203
388	Neurohormonal activation in severe heart failure: Relations to patient death and the effect of treatment with flosequinan. American Heart Journal, 2000, 139, 587-595.	2.7	42
389	Current perspectives on the design of phase II trials of new drugs for the treatment of heart failure. American Heart Journal, 2000, 139, S202-S206.	2.7	15
390	Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction. American Heart Journal, 2000, 139, 503-510.	2.7	48
391	Circadian rhythm and sudden death in heart failure. Journal of the American College of Cardiology, 2000, 36, 541-546.	2.8	56
392	Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure. Circulation, 1999, 100, 2312-2318.	1.6	1,031
393	The REMATCH trial: rationale, design, and end points. Annals of Thoracic Surgery, 1999, 67, 723-730.	1.3	336
394	Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study. European Journal of Heart Failure, 1999, 1, 73-79.	7.1	16
395	Sudden death in heart failure: vascular or electrical?. European Journal of Heart Failure, 1999, 1, 41-45.	7.1	69
396	β-adrenergic blockade in chronic heart failure: Principles, progress, and practice. Progress in Cardiovascular Diseases, 1998, 41, 39-52.	3.1	99

#	Article	IF	CITATIONS
397	\$beta;-Blockade in Heart FailureBasic Concepts and Clinical Results. American Journal of Hypertension, 1998, 11, 23S-37S.	2.0	35
398	Clinical predictors of worsening heart failure during withdrawal from digoxin therapy. American Heart Journal, 1998, 135, 389-397.	2.7	13
399	Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. Journal of Cardiac Failure, 1998, 4, 3-8.	1.7	38
400	Clinical Effects of Î ² -Adrenergic Blockade in Chronic Heart Failure. Circulation, 1998, 98, 1184-1191.	1.6	553
401	Do beta-blockers prolong survival in chronic heart failure? A review of the experimental and clinical evidence. European Heart Journal, 1998, 19 Suppl B, B40-6.	2.2	0
402	End of the Oldest Controversy in Medicine — Are We Ready to Conclude the Debate on Digitalis?. New England Journal of Medicine, 1997, 336, 575-576.	27.0	57
403	Safety and efficacy of carvedilol in severe heart failure. Journal of Cardiac Failure, 1997, 3, 173-179.	1.7	197
404	Coronary Endothelial Dysfunction Precedes Heart Failure and Reduction of Coronary Reserve in Awake Dogs. Journal of Molecular and Cellular Cardiology, 1997, 29, 217-227.	1.9	42
405	Patients With Mild Heart Failure Worsen During Withdrawal From Digoxin Therapy. Journal of the American College of Cardiology, 1997, 30, 42-48.	2.8	46
406	Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure. American Journal of Cardiology, 1997, 80, 1101-1104.	1.6	74
407	Effects of Beta-Adrenergic Blockade on Survival of Patients With Chronic Heart Failure. American Journal of Cardiology, 1997, 80, 46L-54L.	1.6	36
408	Physical Training Alters the Pathogenesis of Pacing-Induced Heart Failure Through Endothelium-Mediated Mechanisms in Awake Dogs. Circulation, 1997, 96, 2683-2692.	1.6	45
409	Effect of Amlodipine on Morbidity and Mortality in Severe Chronic Heart Failure. New England Journal of Medicine, 1996, 335, 1107-1114.	27.0	1,141
410	Changes in plasma endothelin-1 levels reflect clinical response to β-blockade in chronic heart failure. American Heart Journal, 1996, 131, 337-341.	2.7	91
411	Importance of assessing changes in ventricular response to atrial fibrillation during evaluation of new heart failure therapies: Experience from trials of flosequinan. American Heart Journal, 1996, 132, 130-136.	2.7	7
412	Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice?. Journal of the American College of Cardiology, 1996, 28, 1323-1327.	2.8	85
413	Prediction of maximal oxygen consumption by six minute walk testing in patients with congestive heart failure. Journal of the American College of Cardiology, 1996, 27, 216-217.	2.8	0
414	Nitric oxide (NO) is the mediator responsible for physical training-normalized vasodilation of epicardial coronary artery during development of heart failure (HF). Journal of the American College of Cardiology, 1996, 27, 322.	2.8	1

#	Article	IF	CITATIONS
415	Circadian rhythm and sudden death in heart failure: Results from praise. Journal of the American College of Cardiology, 1996, 27, 280.	2.8	1
416	The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure. New England Journal of Medicine, 1996, 334, 1349-1355.	27.0	4,294
417	Beta-blockade in the management of chronic heart failure: Another step in the conceptual evolution of a neurohormonal model of the disease. European Heart Journal, 1996, 17, 21-23.	2.2	20
418	New concepts in the pathophysiology of heart failure: beneficial and deleterious interaction of endogenous haemodynamic and neurohormonal mechanisms. Journal of Internal Medicine, 1996, 239, 327-333.	6.0	41
419	Double-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure. Circulation, 1996, 94, 2793-2799.	1.6	530
420	Carvedilol Inhibits Clinical Progression in Patients With Mild Symptoms of Heart Failure. Circulation, 1996, 94, 2800-2806.	1.6	526
421	Hemodynamic and Renal Excretory Effects of Human Brain Natriuretic Peptide Infusion in Patients With Congestive Heart Failure. Circulation, 1996, 94, 3184-3189.	1.6	265
422	Effects of levosimendan on myocardial contractility and oxygen consumption. Journal of Pharmacology and Experimental Therapeutics, 1996, 279, 120-7.	2.5	34
423	Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. European Heart Journal, 1995, 16, 4-6.	2.2	54
424	Role of endothelin in the exercise intolerance of chronic heart failure. American Journal of Cardiology, 1995, 75, 1282-1283.	1.6	83
425	Lymphocyte G proteins reflect response to treatment in congestive heart failure. American Heart Journal, 1995, 129, 98-106.	2.7	4
426	Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure. Journal of the American College of Cardiology, 1995, 25, 289-294.	2.8	178
427	901-74 Delayed and Incomplete Reversal of Impaired Metabolic Vasodilation in Patients with Heart Failure During Long-term Circulatory Support with a Left Ventricular Assist Device. Journal of the American College of Cardiology, 1995, 25, 22A-23A.	2.8	0
428	965-51 Daily Coronary Microembolization in Awake Dogs Leads to Heart Failure. Journal of the American College of Cardiology, 1995, 25, 222A-223A.	2.8	2
429	757-5 Hemodynamic Effects of Synthetic Human Brain Natriuretic Peptide Infusion in Patients with Severe Congestive Heart Failure: A Placebo-controlled, Crossover Trial. Journal of the American College of Cardiology, 1995, 25, 235A.	2.8	0
430	Reversal of Chronic Ventricular Dilation in Patients With End-Stage Cardiomyopathy by Prolonged Mechanical Unloading. Circulation, 1995, 91, 2717-2720.	1.6	348
431	Is Tumor Necrosis Factor an Important Neurohormonal Mechanism in Chronic Heart Failure?. Circulation, 1995, 92, 1379-1382.	1.6	115
432	Double-Blind, Placebo-Controlled Study of the Long-term Efficacy of Carvedilol in Patients With Severe Chronic Heart Failure. Circulation, 1995, 92, 1499-1506.	1.6	316

#	Article	IF	CITATIONS
433	Guidelines for the Evaluation and Management of Heart Failure. Circulation, 1995, 92, 2764-2784.	1.6	407
434	A novel approach to the development of positive inotropic agents for chronic heart failure. Journal of Cardiovascular Pharmacology, 1995, 26 Suppl 1, S52-6.	1.9	3
435	N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction Circulation, 1994, 89, 1934-1942.	1.6	232
436	Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators Circulation, 1994, 90, 1731-1738.	1.6	311
437	Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: Effect of captopril. Journal of the American College of Cardiology, 1994, 24, 583-591.	2.8	274
438	Potential of left ventricular assist devices as outpatient therapy while awaiting transplantation. Annals of Thoracic Surgery, 1994, 58, 1515-1520.	1.3	89
439	Calcium antagonists for congestive heart failure: Evolving concepts in bridge building. Cardiovascular Drugs and Therapy, 1993, 7, 95-96.	2.6	10
440	How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. American Journal of Cardiology, 1993, 71, C3-C11.	1.6	110
441	Withdrawal of Digoxin from Patients with Chronic Heart Failure Treated with Angiotensin-Converting-Enzyme Inhibitors. New England Journal of Medicine, 1993, 329, 1-7.	27.0	853
442	Activation of neurohumoral systems in postinfarction left ventricular dysfunction. Journal of the American College of Cardiology, 1993, 22, 390-398.	2.8	149
443	Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: The Promise Study. Journal of the American College of Cardiology, 1993, 21, 634-640.	2.8	69
444	Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors. Journal of the American College of Cardiology, 1993, 22, 963-967.	2.8	14
445	Discussion II. Journal of the American College of Cardiology, 1993, 22, A41-A42.	2.8	0
446	Discussion VII. Journal of the American College of Cardiology, 1993, 22, A162-A164.	2.8	0
447	Discussion IX. Journal of the American College of Cardiology, 1993, 22, A192-A193.	2.8	0
448	Panel discussion I: Evaluation and management of chronic heart failure. Journal of the American College of Cardiology, 1993, 22, A201-A203.	2.8	1
449	Panel discussion II: Directions for future research. Journal of the American College of Cardiology, 1993, 22, A204-A205.	2.8	0
450	Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Journal of the American College of Cardiology, 1993, 22, 65-72.	2.8	128

#	Article	IF	CITATIONS
451	The Search for the Ideal Positive Inotropic Agent. New England Journal of Medicine, 1993, 329, 201-202.	27.0	72
452	Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET) Circulation, 1993, 88, 492-501.	1.6	97
453	Simultaneous Modeling of the Pharmacokinetic and Pharmacodynamic Properties of Enalkiren (Abbott-64662, A Renin Inhibitor). II. Journal of Cardiovascular Pharmacology, 1993, 21, 834-840.	1.9	8
454	Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction. New England Journal of Medicine, 1992, 327, 669-677.	27.0	5,567
455	Treatment of chronic heart failure. Lancet, The, 1992, 340, 92-95.	13.7	80
456	Pathophysiology of chronic heart failure. Lancet, The, 1992, 340, 88-92.	13.7	362
457	The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. Journal of the American College of Cardiology, 1992, 20, 248-254.	2.8	956
458	Ophthalmology's botanical heritage. Survey of Ophthalmology, 1992, 36, 357-365.	4.0	8
459	The effect of treatment on survival in congestive heart failure. Clinical Cardiology, 1992, 15, 323-329.	1.8	11
460	Lack of relation between ventricular arrhythmias and sudden death in patients with chronic heart failure. Circulation, 1992, 85, I50-6.	1.6	40
461	Management of patients with heart failure and angina: Do coexistent diseases alter the response to cardiovascular drugs?. Journal of the American College of Cardiology, 1991, 17, 740-742.	2.8	10
462	Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure. New England Journal of Medicine, 1991, 325, 1468-1475.	27.0	2,137
463	Is the erythrocyte sedimentation rate a useful marker of the response to therapy in heart failure? A re-evaluation after 50 years. Journal of the American College of Cardiology, 1991, 17, A89.	2.8	0
464	Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure. American Journal of Cardiology, 1991, 67, 63-66.	1.6	36
465	Sex Differences in the Management of Coronary Artery Disease. New England Journal of Medicine, 1991, 325, 226-230.	27.0	847
466	The Erythrocyte Sedimentation Rate in Congestive Heart Failure. New England Journal of Medicine, 1991, 324, 353-358.	27.0	66
467	Diastolic function as a target of therapeutic interventions in chronic heart failure. European Heart Journal, 1990, 11, 35-40.	2.2	7
468	Clinical and regulatory implications of the cardiac arrhythmia suppression trial. American Journal of Cardiology, 1990, 65, 103-105.	1.6	51

#	Article	IF	CITATIONS
469	Congestive heart failure: Current controversies and future prospects. American Journal of Cardiology, 1990, 66, 429-430.	1.6	40
470	Are nitrates effective in the treatment of chronic heart failure? Antagonist's viewpoint. American Journal of Cardiology, 1990, 66, 458-461.	1.6	10
471	Elevated Circulating Levels of Tumor Necrosis Factor in Severe Chronic Heart Failure. New England Journal of Medicine, 1990, 323, 236-241.	27.0	2,370
472	Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure Circulation, 1990, 81, 860-864.	1.6	62
473	Calcium channel blockers in chronic heart failure. The risks of "physiologically rational" therapy Circulation, 1990, 82, 2254-2257.	1.6	118
474	Primary pulmonary hypertension associated with human immunodeficiency viral infection. American Journal of Medicine, 1990, 89, 96-99.	1.5	92
475	The placebo effect in heart failure. American Heart Journal, 1990, 120, 1579-1582.	2.7	37
476	Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. Journal of the American College of Cardiology, 1990, 16, 827-831.	2.8	110
477	How do vasodilators improve cardiac performance in chronic heart failure? Insights gained from two-dimensional color flow Doppler echocardiography. Journal of the American College of Cardiology, 1990, 15, A150.	2.8	2
478	Due process. Western Journal of Medicine, 1990, 153, 91-2.	0.3	0
479	Abnormalities of diastolic function as a potential cause of exercise intolerance in chronic heart failure. Circulation, 1990, 81, III78-86.	1.6	68
480	Pathophysiological mechanisms underlying the effects of beta-adrenergic agonists and antagonists on functional capacity and survival in chronic heart failure. Circulation, 1990, 82, 177-88.	1.6	16
481	Role of the sympathetic nervous system in chronic heart failure. A historical and philosophical perspective. Circulation, 1990, 82, 11-6.	1.6	5
482	Adverse Hemodynamic and Clinical Effects of Encainide in Severe Chronic Heart Failure. Annals of Internal Medicine, 1989, 110, 505.	3.9	30
483	Therapeutic options in the management of chronic heart failure. Is there a drug of first choice?. Circulation, 1989, 79, 198-204.	1.6	52
484	Combined Beta-Adrenergic and Calcium-Entry Blockade in Angina Pectoris. New England Journal of Medicine, 1989, 320, 709-718.	27.0	128
485	Is It Ethical to Administer Vasodilator Drugs to Patients with Primary Pulmonary Hypertension?. Chest, 1989, 95, 1173-1175.	0.8	23
486	Does digitalis work in chronic heart failure? The end of a 200-year-old controversy. Cardiovascular Drugs and Therapy, 1989, 2, 743-746.	2.6	2

#	Article	IF	CITATIONS
487	Deleterious hemodynamic effects of lidocaine in severe congestive heart failure. American Heart Journal, 1989, 118, 611-612.	2.7	17
488	Predictors of total mortality and sudden death in mild to moderate heart failure. Journal of the American College of Cardiology, 1989, 14, 564-570.	2.8	388
489	Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. Journal of the American College of Cardiology, 1989, 13, 1534-1539.	2.8	342
490	Second generation calcium channel blockers in the treatment of chronic heart failure: Are they any better than their predecessors?*. Journal of the American College of Cardiology, 1989, 14, 1339-1342.	2.8	21
491	The clinical significance of nitrate tolerance in patients with chronic heart failure. European Heart Journal, 1989, 10, 20-25.	2.2	12
492	Cardiac failure: editorial overview. Current Opinion in Cardiology, 1989, 4, 339-341.	1.8	2
493	Is activation of the sympathetic nervous system beneficial or detrimental to the patient with chronic heart failure? Lessons learned from clinical trials with beta-adrenergic agonists and antagonists. Journal of Cardiovascular Pharmacology, 1989, 14 Suppl 5, S38-43.	1.9	4
494	The current status of angiotensin converting enzyme inhibitors in the management of patients with chronic heart failure. Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension, 1989, 7, S33-6.	0.1	15
495	Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure. Circulation, 1989, 80, IV59-67.	1.6	27
496	Foreword. Journal of the American College of Cardiology, 1988, 12, 262-264.	2.8	5
497	II. Protagonist's viewpoint. Journal of the American College of Cardiology, 1988, 12, 562-566.	2.8	19
498	Vasodilator and inotropic drugs for the treatment of chronic heart failure: Distinguishing hype from hope. Journal of the American College of Cardiology, 1988, 12, 1299-1317.	2.8	118
499	Neurohormonal interactions and adaptations in congestive heart failure Circulation, 1988, 77, 721-730.	1.6	564
500	Prevention and Reversal of Nitrate Tolerance in Patients with Congestive Heart Failure. Survey of Anesthesiology, 1988, 32, 86.	0.1	3
501	Cumulative Hemodynamic Response to Short-Term Treatment with Flosequinan (BTS 49465), a New Direct-Acting Vasodilator Drug, in Severe Chronic Congestive Heart Failure. Journal of Cardiovascular Pharmacology, 1988, 12, 6-11.	1.9	36
502	Clinical Trials in Congestive Heart Failure: Why Do Studies Report Conflicting Results?. Annals of Internal Medicine, 1988, 109, 3.	3.9	11
503	Modulation of functional capacity and survival in congestive heart failure. Effects of activation of the sympathetic nervous system. Postgraduate Medicine, 1988, Spec No, 96-103.	2.0	1
504	Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure. Circulation, 1988, 77, 164-73.	1.6	15

#	Article	IF	CITATIONS
505	Do Vasodilators Prolong Life in Heart Failure?. New England Journal of Medicine, 1987, 316, 1471-1473.	27.0	32
506	Functional Renal Insufficiency During Long-Term Therapy with Captopril and Enalapril in Severe Chronic Heart Failure. Annals of Internal Medicine, 1987, 106, 346.	3.9	188
507	Influence of diabetes mellitus on changes in left ventricular performance and renal function produced by converting enzyme inhibition in patients with severe chronic heart failure. American Journal of Medicine, 1987, 82, 1119-1126.	1.5	33
508	Hemodynamic effects of BTS 49465, a new long-acting systemic vasodilator drug, in patients with severe congestive heart failure. American Heart Journal, 1987, 113, 137-143.	2.7	58
509	Prognostic importance of the immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction. Journal of the American College of Cardiology, 1987, 10, 1303-1311.	2.8	69
510	Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. Journal of the American College of Cardiology, 1987, 10, 837-844.	2.8	84
511	How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blind men. Journal of the American College of Cardiology, 1987, 9, 433-438.	2.8	97
512	Prevention and Reversal of Nitrate Tolerance in Patients with Congestive Heart Failure. New England Journal of Medicine, 1987, 317, 799-804.	27.0	378
513	Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. American Journal of Cardiology, 1987, 60, 179-184.	1.6	51
514	Comparative hemodynamic and clinical effects of long-term treatment with prazosin and captopril for severe chronic congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. American Journal of Cardiology, 1986, 57, 1323-1327.	1.6	39
515	Systemic vasoconstrictor effects of oxygen administration in obliterative pulmonary vascular disorders. American Journal of Cardiology, 1986, 57, 853-858.	1.6	17
516	Hemodynamic factors limiting the response to transdermal nitroglycerin in severe chronic congestive heart failure. American Journal of Cardiology, 1986, 57, 260-267.	1.6	70
517	Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure. American Journal of Cardiology, 1986, 57, 347-348.	1.6	45
518	Hormone-electrolyte interactions in the pathogenesis of lethal cardiac arrhythmias in patients with congestive heart failure: Basis of a new physiologic approach to control of arrhythmia. American Journal of Medicine, 1986, 80, 23-29.	1.5	302
519	Role of the renin-angiotensin system in the development of hemodynamic and clinical tolerance to long-term prazosin therapy in patients with severe chronic heart failure. Journal of the American College of Cardiology, 1986, 7, 671-680.	2.8	46
520	Influence of Renal Function on the Hemodynamic and Clinical Responses to Long-Term Captopril Therapy in Severe Chronic Heart Failure. Annals of Internal Medicine, 1986, 104, 147.	3.9	31
521	Comparison of Captopril and Enalapril in Patients with Severe Chronic Heart Failure. New England Journal of Medicine, 1986, 315, 847-853.	27.0	302
522	Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure Circulation, 1986, 73, 257-267.	1.6	556

#	Article	IF	CITATIONS
523	Preservation of glomerular filtration rate in human heart failure by activation of the renin-angiotensin system Circulation, 1986, 74, 766-774.	1.6	101
524	Comparative Immediate Hemodynamic and Hormonal Effects of Amrinone and Captopril in Patients with Severe Chronic Heart Failure. American Journal of the Medical Sciences, 1986, 291, 8-15.	1.1	6
525	Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management. Postgraduate Medical Journal, 1986, 62 Suppl 1, 179-82.	1.8	11
526	Vasodilator Therapy for Primary Pulmonary Hypertension. Annals of Internal Medicine, 1985, 103, 258.	3.9	122
527	Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial Circulation, 1985, 71, 963-971.	1.6	209
528	Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catheterization in patients with chronic heart failure Circulation, 1985, 71, 761-766.	1.6	137
529	Sudden unexpected death in patients with congestive heart failure: a second frontier Circulation, 1985, 72, 681-685.	1.6	371
530	Converting-enzyme inhibition for severe chronic heart failure: views from a skeptic. International Journal of Cardiology, 1985, 7, 111-120.	1.7	30
531	Hemodynamic and clinical significance of the pulmonary vascular response to long-term captopril therapy in patients with severe chronic heart failure. Journal of the American College of Cardiology, 1985, 6, 635-645.	2.8	29
532	Is the renin-angiotensin system really unnecessary in patients with severe chronic heart failure: The price we pay for interfering with evolution. Journal of the American College of Cardiology, 1985, 6, 171-173.	2.8	20
533	Comparative effects of captopril and isosorbide dinitrate on pulmonary arteriolar resistance and right ventricular function in patients with severe left ventricular failure: Results of a randomized crossover study. American Heart Journal, 1985, 109, 1293-1299.	2.7	30
534	Mechanisms of nitrate action in patients with severe left ventricular failure: Conceptual problems with the theory of venosequestration. American Heart Journal, 1985, 110, 259-264.	2.7	16
535	Does pulmonary vasoconstriction play an important role in patients with primary pulmonary hypertension? A skeptic's view of vasodilator therapy. Chest, 1985, 88, 265S-268.	0.8	2
536	Correction of Dilutional Hyponatremia in Severe Chronic Heart Failure by Converting-Enzyme Inhibition. Annals of Internal Medicine, 1984, 100, 782.	3.9	118
537	Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure Circulation, 1984, 70, 1038-1047.	1.6	237
538	Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease. Journal of the American College of Cardiology, 1984, 4, 890-901.	2.8	96
539	Relation between exercise-induced changes in ejection fraction and systolic loading conditions at rest in aortic regurgitation. Journal of the American College of Cardiology, 1984, 3, 924-929.	2.8	45
540	Relation between serum sodium concentration and the hemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure. Journal of the American College of Cardiology, 1984, 3, 1035-1043.	2.8	117

#	Article	IF	CITATIONS
541	Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure. American Journal of Cardiology, 1984, 54, 1025-1029.	1.6	21
542	Efficacy of captopril in low-renin congestive heart failure: Importance of sustained reactive hyperreninemia in distinguishing responders from nonresponders. American Journal of Cardiology, 1984, 54, 771-777.	1.6	35
543	Conceptual dilemmas in the classification of vasodilator drugs for severe chronic heart failure. American Journal of Medicine, 1984, 76, 3-13.	1.5	26
544	Nitroglycerin therapy in the management of pulmonary hypertensive disorders. American Journal of Medicine, 1984, 76, 67-75.	1.5	73
545	Prostaglandins in Severe Congestive Heart Failure. New England Journal of Medicine, 1984, 310, 347-352.	27.0	417
546	New perspectives on therapeutic application of nitrates as vasodilator agents for severe chronic heart failure. American Journal of Medicine, 1983, 74, 61-72.	1.5	32
547	Quantitative differences in the hemodynamic effects of captopril and nitroprusside in severe chronic heart failure. American Journal of Cardiology, 1983, 51, 183-188.	1.6	26
548	Hemodynamic responses to combined therapy with captopril and hydralazine in patients with severe heart failure. Journal of the American College of Cardiology, 1983, 2, 338-344.	2.8	31
549	Vasodilator and inotropic therapy for severe chronic heart failure: Passion and skepticism. Journal of the American College of Cardiology, 1983, 2, 841-852.	2.8	133
550	Indications for left ventricular aneurysmectomy Circulation, 1983, 67, 717-722.	1.6	85
551	Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure Circulation, 1983, 68, 803-812.	1.6	133
552	Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man Circulation, 1982, 65, 660-668.	1.6	420
553	Deleterious Effects of Hydralazine in Patients with Pulmonary Hypertension. New England Journal of Medicine, 1982, 306, 1326-1331.	27.0	221
554	Hemodynamic Characterization of Tolerance to Long-Term Hydralazine Therapy in Severe Chronic Heart Failure. New England Journal of Medicine, 1982, 306, 57-62.	27.0	106
555	Central hemodynamic effects of dipyridamole in severe heart failure: Comparison with hydralazine. Clinical Pharmacology and Therapeutics, 1982, 32, 54-61.	4.7	7
556	Contrasting hemodynamic responses in severe heart failure: Comparison of captopril and other vasodilator drugs. American Heart Journal, 1982, 104, 1215-1223.	2.7	25
557	Clinical relevance of verapamil plasma levels in stable angina pectoris. American Journal of Cardiology, 1982, 50, 1180-1184.	1.6	74
558	Long-term effectiveness of verapamil in stable and unstable angina pectoris. American Journal of Cardiology, 1982, 50, 1185-1190.	1.6	40

#	Article	IF	CITATIONS
559	Verapamil therapy for stable and unstable angina pectoris: Calcium channel antagonists in perspective. American Journal of Cardiology, 1982, 50, 881-885.	1.6	28
560	Pharmacologic and hemodynamic mechanisms underlying the antianginal actions of verapamil. American Journal of Cardiology, 1982, 50, 886-893.	1.6	30
561	Hemodynamic and clinical effects of combined verapamil and propranolol therapy in angina pectoris. American Journal of Cardiology, 1982, 50, 903-912.	1.6	48
562	Selection of Vasodilator Drugs for Patients with Severe Chronic Heart Failure. Drugs, 1982, 24, 64-74.	10.9	12
563	Physiologic and pharmacologic determinants of vasodilator response: A conceptual framework for rational drug therapy for chronic heart failure. Progress in Cardiovascular Diseases, 1982, 24, 275-292.	3.1	69
564	Provocation of myocardial ischemic events during initiation of vasodilator therapy for severe chronic heart failure. American Journal of Cardiology, 1981, 48, 939-946.	1.6	37
565	Quantification of valve regurgitation by radionuclide angiography before and after valve replacement surgery. American Journal of Cardiology, 1981, 47, 287-291.	1.6	57
566	Sustained effectiveness of minoxidil in heart failure after development of tolerance to other vasodilator drugs. American Journal of Cardiology, 1981, 48, 375-379.	1.6	18
567	Effects of sudden change in cycle length on human atrial, atrioventricular nodal and ventricular refractory periods Circulation, 1981, 64, 245-248.	1.6	66
568	Determinants of drug response in severe chronic heart failure. 1. Activation of vasoconstrictor forces during vasodilator therapy Circulation, 1981, 64, 506-514.	1.6	103
569	Is There a Drug of Choice for Vasodilator Therapy in Patients with Refractory Heart Failure?. Chest, 1980, 77, 7-9.	0.8	5
570	Hemodynamic evaluation of hydralazine dosage in refractory heart failure. Clinical Pharmacology and Therapeutics, 1980, 27, 337-346.	4.7	31
571	Importance of Left Ventricular Chamber Size in Determining the Response to Hydralazine in Severe Chronic Heart Failure. New England Journal of Medicine, 1980, 303, 250-255.	27.0	98
572	Dose requirements of hydralazine in patients with severe chronic congestive heart failure. American Journal of Cardiology, 1980, 45, 655-660.	1.6	99
573	Rebound Hemodynamic Events after the Abrupt Withdrawal of Nitroprusside in Patients with Severe Chronic Heart Failure. New England Journal of Medicine, 1979, 301, 1193-1197.	27.0	126
574	Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure Circulation, 1979, 59, 531-539.	1.6	237
575	Prognostic value of echocardiographic evaluation of septal function in acute anteroseptal myocardial infarction. American Heart Journal, 1979, 97, 726-732.	2.7	14
576	Differences in hemodynamic effects of nitroprusside and prazosin in severe chronic congestive heart failure. American Journal of Cardiology, 1979, 44, 310-317.	1.6	28

#	Article	IF	CITATIONS
577	Link Between Synovial and Myocardial Inflammation: Conceptual Framework to Explain the Pathogenesis of Heart Failure with Preserved Ejection Fraction in Patients with Systemic Rheumatic Diseases. Cardiac Failure Review, 0, 6, .	3.0	1